Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004103 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy Followed by Surgery in Treating Patients With Stomach Cancer
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00004103: Completed Phase 2 study, sponsored by NYU Langone Health.
NCT00004103 is a Phase 2 study that has completed, run by NYU Langone Health. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004103, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and combining chemotherapy with surgery may kill more tumor cells. PURPOSE: This phase II trial is studying how well irinotecan and cisplatin followed by surgery, floxuridine, and cisplatin work in treating patients with stomach cancer.
Interventions
- DRUG cisplatin
- PROCEDURE conventional surgery
- PROCEDURE adjuvant therapy
- DRUG floxuridine
- DRUG irinotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-07 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
What the finished NCT00004103 record still lists
NCT00004103 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00004103 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004103 about?
NCT00004103 is a clinical study titled "Combination Chemotherapy Followed by Surgery in Treating Patients With Stomach Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and combining chemotherapy with surgery may kill more tumor cells. PURPOSE: This phase II trial is studying how well irinotecan and cisplatin followed...
What is the current status of trial NCT00004103?
This trial is currently completed. It is a Phase 2 study. The study started on 1998-07. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00004103?
The interventions under investigation include: cisplatin (DRUG), conventional surgery (PROCEDURE), adjuvant therapy (PROCEDURE), floxuridine (DRUG), irinotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00004103?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia